These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 37457288)

  • 1. Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer.
    Geng P; Chi Y; Yuan Y; Yang M; Zhao X; Liu Z; Liu G; Liu Y; Zhu L; Wang S
    Front Cell Dev Biol; 2023; 11():1158539. PubMed ID: 37457288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy.
    Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil.
    Nasiri F; Kazemi M; Mirarefin SMJ; Mahboubi Kancha M; Ahmadi Najafabadi M; Salem F; Dashti Shokoohi S; Evazi Bakhshi S; Safarzadeh Kozani P; Safarzadeh Kozani P
    Front Immunol; 2022; 13():1018786. PubMed ID: 36483567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
    Dees S; Ganesan R; Singh S; Grewal IS
    Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
    Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
    Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both
    Xia L; Zheng ZZ; Liu JY; Chen YJ; Ding JC; Xia NS; Luo WX; Liu W
    Clin Transl Immunology; 2020 May; 9(5):e01135. PubMed ID: 32373345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
    Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
    Front Immunol; 2020; 11():573823. PubMed ID: 33072116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and challenges of immunotherapy in triple-negative breast cancer.
    Zhu Y; Zhu X; Tang C; Guan X; Zhang W
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer.
    Shewale H; Kanugo A
    Curr Pharm Biotechnol; 2024 Jul; ():. PubMed ID: 39092645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T-cell therapy for triple-negative breast cancer: Where we are.
    Xie Y; Hu Y; Zhou N; Yao C; Wu L; Liu L; Chen F
    Cancer Lett; 2020 Oct; 491():121-131. PubMed ID: 32795486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress.
    Corti C; Venetis K; Sajjadi E; Zattoni L; Curigliano G; Fusco N
    Expert Opin Investig Drugs; 2022 Jun; 31(6):593-605. PubMed ID: 35311430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
    Han Y; Xie W; Song DG; Powell DJ
    J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
    Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y
    Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling.
    Zhou M; Chen M; Shi B; Di S; Sun R; Jiang H; Li Z
    Mol Ther; 2022 Nov; 30(11):3379-3393. PubMed ID: 35927951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC.
    Liu Y; Zhou Y; Huang KH; Li Y; Fang X; An L; Wang F; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
    Aging (Albany NY); 2019 Dec; 11(23):11054-11072. PubMed ID: 31804974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in antibody-based therapeutics for triple-negative breast cancer.
    Ning WJ; Liu X; Zeng HY; An ZQ; Luo WX; Xia NS
    Expert Opin Drug Deliv; 2022 Jul; 19(7):815-832. PubMed ID: 35738312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.
    Hu Z
    Sci Rep; 2020 Feb; 10(1):2815. PubMed ID: 32071339
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Stüber T; Monjezi R; Wallstabe L; Kühnemundt J; Nietzer SL; Dandekar G; Wöckel A; Einsele H; Wischhusen J; Hudecek M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.